An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from ¿ìè¶ÌÊÓƵ
Explore the latest news, articles and features
Popular articles
Trending ¿ìè¶ÌÊÓƵ articles
1
The best new science-fiction books of June 2026
2
Pancreatic cancer halted by virus injection in three patients
3
Glaciers in the 'roof of the world' have suddenly started melting
4
Red-light therapy does have health benefits but not the ones you think
5
Photons behave very strangely if you try to cut them
6
Mathematical AI helps researchers crack 50-year-old problem
7
Millions of planets might form around supermassive black holes
8
Q-Day could destroy bitcoin – and our retirement savings
9
Embryos made without sperm or eggs reveal why many pregnancies fail
10
Rebooting stem cells builds aged muscles and assists injury recovery
